Feline lower urinary tract disease and idiopathic cystitis (FLUTD / FIC)
Feline idiopathic cystitis (FIC), Feline interstitial cystitis, FLUTD, Feline urologic syndrome (FUS, obsolete term), Blocked cat / urethral obstruction (the emergency form), Pandora syndrome (Buffington's term for the whole-cat version of FIC)
Feline lower urinary tract disease is a group of signs, not one illness: straining to pee, peeing tiny amounts over and over, blood in the urine, crying in the litter box, or suddenly peeing outside it. Several different problems can cause exactly the same picture, so your veterinarian has to test to find out which one your cat has. In most cats every test comes back clean, and that is called idiopathic cystitis - 'idiopathic' simply means we cannot find a cause. The part every cat owner needs to know: if a cat, especially a male cat, is straining and no urine is coming out, that can be a complete blockage, and a blocked cat can die within a day or two. That is an emergency room visit right now, not a wait-and-see. The good news is that most cats with idiopathic cystitis get better with pain relief, more water in their food, and changes at home, and the episodes usually settle down over time.
What you might notice
- Going to the litter box far more often than usual, and producing only a few drops each time
- Straining, hunching or pushing in the box - it can look like constipation, so people often mistake it for that
- Pink, red or rusty-coloured urine, or spots of blood on the litter or bedding
- Crying, growling or yowling while in the box, or bolting out of it as if startled
- Peeing outside the box - on cool smooth surfaces like tile, a bathtub, a sink, or on bedding and laundry
- Licking at the genital area much more than usual, sometimes until the fur is wet or thin
- Restlessness, pacing, hiding, or not wanting to be picked up around the belly
- In between episodes the cat often looks completely normal, which is why owners wonder if they imagined it
Standard of care
Relieve urethral obstruction as an emergency - this is the intervention that saves lives
Approved / guideline-backedAn obstructed cat needs immediate decompression of the bladder, intravenous fluid therapy, correction of hyperkalaemia and acidosis, sedation and analgesia, and usually placement of an indwelling urinary catheter with a closed collection system for a short defined period. Nothing else in this protocol matters until the cat can pass urine. Owners must be told plainly that the risk is measured in hours and that re-obstruction in the first days is common.
Named products: There is NO FDA-approved drug for urethral obstruction or for feline idiopathic cystitis. Every drug used in this emergency is used extralabel in cats. The only FDA-approved feline buprenorphine product, SIMBADOL (buprenorphine injection, 1.8 mg/mL, NADA 141-434, Zoetis Inc., CIII), is labelled specifically for 'the control of postoperative pain associated with surgical procedures in cats' at 0.24 mg/kg SC once daily for up to 3 days - so its use for cystitis or obstruction pain is extralabel and must be presented as such.
The 2025 iCatCare consensus guidelines state that urethral obstruction is a life-threatening complication of various underlying lower urinary tract diseases and devote a dedicated section to it alongside catheterisation. In an 82-case series with 82 matched controls, overall mortality was 8.5%, and recurrence was 22% at 6 months and 24% at 2 years; ionised calcium was significantly higher in survivors than non-survivors. Species: CAT.
Treat the pain - in every cat, obstructed or not
Approved / guideline-backedFIC is a painful inflammatory condition and pain is the sign owners can actually see. Opioid analgesia is the backbone in the acute phase; in published feline protocols buprenorphine was used at 0.01 mg/kg SC every 8 hours in hospital, and at 0.075 mg PO every 8 hours in an outpatient-style protocol. A key honesty point for clients: in a placebo-controlled trial of obstructive FIC, general demeanour and pain on abdominal palpation improved significantly in BOTH groups during hospitalisation, and most cats still had clinical signs one week after presentation - so analgesia should be planned for longer than the hospital stay, not stopped at discharge.
Named products: Buprenorphine (extralabel for this indication; SIMBADOL, NADA 141-434, is approved in cats only for postoperative pain). Acepromazine and medetomidine were used as sedative adjuncts in the published non-catheter protocol. DO NOT reach for acetaminophen/paracetamol in any form - it is absolutely contraindicated in cats. NSAIDs are covered separately below and should not be given to a dehydrated, azotaemic or obstructed cat.
The 2022 ISFM consensus guidelines on acute pain in cats note that the unique challenges of feline metabolism and comorbidities may lead to undertreatment of pain. Buprenorphine dosing as above is taken directly from two published feline FLUTD protocols: 0.01 mg/kg SC q8h on days 0-1 in all 37 cats of a randomised obstructive-FIC trial, and 0.075 mg PO q8h in a 15-cat clinical trial of non-catheter management. The same randomised trial documented that persistence of clinical signs in most cats one week after presentation indicates symptomatic treatment for a longer period is warranted. Species: CAT.
Get water into the cat - switch to canned (wet) food and increase water intake
Controlled trial in this speciesThis is the single best-supported long-term intervention in idiopathic cystitis and it costs nothing but a change of habit. Feeding the canned rather than the dry version of the SAME therapeutic diet cut recurrence substantially over 12 months. The mechanism is dilution: urine specific gravity fell measurably in cats whose owners switched to more canned food. Practical delivery matters more than product choice - canned food, water added to food, several wide bowls away from food and litter, a running fountain if the cat likes one.
Named products: Not a drug. Diet form (canned versus dry) is the active variable. Do NOT assume any urinary diet is appropriate for every cat: acidifying, low-magnesium struvite-preventive diets are wrong for calcium oxalate and ammonium urate stones, and are not formulated for kittens or for pregnant or lactating queens.
Prospective trial in 54 client-owned cats with idiopathic cystitis fed either the canned or the dry formulation of one commercial urine-acidifying diet, with re-evaluation at 2 and 16 weeks and 6 and 12 months. Signs of lower urinary tract disease did NOT recur in 16 of 18 cats on the canned diet versus 17 of 28 cats on the dry diet (P < 0.05). Independent corroboration of the mechanism: in a separate randomised trial, 36 of 40 owners (90%) began feeding more canned food, and urine specific gravity fell from a mean 1.050 at enrolment to 1.036 one month later (P < 0.01). Species: CAT. Honest limits: the 1999 trial was not randomised to formulation by the investigators in a blinded fashion, 8 cats were lost to follow-up, and owners of most cats that relapsed declined re-examination.
Multimodal environmental modification (MEMO) - litter, water, resources, conflict, predictability
Approved / guideline-backedMEMO means taking a detailed environmental history and then changing what is actually wrong for that individual cat: enough litter boxes in the right places, litter the cat will use, scooped daily, separated resting, feeding, watering and elimination resources, safe elevated places, predictable routine, reduced conflict in multi-cat households, and play or hunting-style enrichment. It is recommended in the governing feline guideline and it is the only long-term intervention with any published feline signal beyond diet. It must be sold honestly: the primary study was uncontrolled.
Prospective OBSERVATIONAL study, 46 client-owned indoor-housed cats with idiopathic cystitis, followed for 10 months after MEMO recommendations were added to usual care. Significant (P < 0.05) reductions in lower urinary tract signs, fearfulness, nervousness and respiratory signs, with a trend (P < 0.1) toward reduced aggression and lower-intestinal signs. The authors' own conclusion is that MEMO is a PROMISING ADJUNCTIVE therapy that should be followed up with prospective controlled clinical trials - it has not been. Counterweight to over-claiming: a natural experiment across 12 months of COVID-19 human movement restrictions found no significant change in FIC or urethral obstruction incidence, which argues against a simple stress-in / cystitis-out model. Species: CAT.
Identify and treat the causes that are NOT idiopathic - stones, plugs, infection, tumours
Approved / guideline-backedRoughly four in ten FLUTD cats have something specific and specifically treatable. Sterile struvite stones dissolve on diet alone and do not need surgery. Documented bacterial UTI needs a culture-directed antibiotic, not an empirical one. A mass in an older cat needs a cancer workup. Getting this step right is what prevents a cat being managed for years as 'stress cystitis' while a stone or a tumour goes untreated.
Named products: Therapeutic low-magnesium, urine-acidifying dissolution diets (products were coded A and B in the trial and are not named in the publication - do not attribute the 13-day figure to a specific brand). Antimicrobials only where culture documents infection; the 2025 iCatCare guidelines address urinary tract infection as a distinct entity from FIC.
Prospective, multicentre, RANDOMISED clinical trial of dietary dissolution in 37 cats with presumed struvite uroliths: 32 of 37 achieved complete dissolution, with mean complete-dissolution time of 13.0 +/- 2.6 days on one food versus 27.0 +/- 2.6 days on the other, and no diet-associated adverse events. Critically, the 5 cats whose stones did NOT dissolve had stones that were 100% ammonium urate (4) or 100% calcium oxalate (1) - i.e. failure to shrink by 2 weeks means misdiagnosis or non-compliance, not 'needs longer'. Treatment and prevention strategy for both struvite and calcium oxalate is set out in the ACVIM small animal consensus recommendations on uroliths. Species: CAT (dissolution trial); CAT and DOG (consensus).
Know what has FAILED in controlled feline trials - and stop paying for it
Controlled trial in this speciesThis is the most commercially inconvenient and clinically valuable part of this protocol. Five of the interventions most often prescribed or sold for feline cystitis have been tested in cats against placebo and did not work. A clinic that keeps dispensing them is charging owners for nothing and, in one case, may be making recurrence worse.
Named products: Meloxicam, prazosin, amitriptyline, pentosan polysulfate sodium, N-acetyl-D-glucosamine. None is FDA-approved for FIC in cats. The glucosamine trial contains the most important lesson on this whole page: the MAJORITY of cats in BOTH arms improved significantly from baseline (P < 0.001), which the authors attribute to 90% of owners switching to more canned food - so a before-and-after improvement in an uncontrolled setting is not evidence that a product worked.
MELOXICAM, obstructive FIC: randomised, placebo-controlled, 37 cats, 5 days oral meloxicam after buprenorphine; recurrent urethral obstruction 4/18 (22%) versus 5/19 (26%) placebo, P = 1.000, and no between-group difference in demeanour, food intake or voiding behaviour (PMID 26672127). PRAZOSIN, recurrent obstruction: randomised, blinded, placebo-controlled, 65 cats completing; recurrence 11/37 (30%) on prazosin versus 5/28 (18%) on placebo, P = 0.27 - numerically worse, not better (PMID 33749375); a second double-blinded trial in 47 cats found no difference at discharge, 1 month or 6 months and reported lethargy, ptyalism, diarrhoea, anorexia and malodorous stool as adverse effects (PMID 28510274). AMITRIPTYLINE, short course in acute non-obstructive disease: randomised controlled trial, 31 cats, 5 mg/day for 7 days; no difference in recovery from pollakiuria or haematuria, and signs recurred significantly FASTER and MORE FREQUENTLY in treated cats (PMID 12675297). INTRAVESICAL PENTOSAN POLYSULFATE, obstructive FIC: randomised, placebo-controlled, blinded, 35 cats; recurrent obstruction 3/18 versus 3/17, P = 1.000, no difference in clinical score (PMID 26116618). ORAL N-ACETYL GLUCOSAMINE: randomised, double-blinded, placebo-controlled, 40 cats, 125 mg/day for 6 months; no significant difference in mean health score (P > 0.5), monthly clinical score (P = 0.22) or days with signs (P = 0.28) (PMID 15265477). Species: CAT for all five.
Therapeutic 'urinary stress' diet containing alpha-casozepine and L-tryptophan - promising, not proven
Early evidenceA diet combining urinary-tract formulation with alpha-casozepine (a milk-protein-derived peptide) and L-tryptophan reduced short-term recurrence in one feline cohort study. It is a reasonable option for a cat that has already had an episode, offered as 'worth trying', never as established. Note that this is the only place in this protocol where a peptide-containing product has ANY supporting feline clinical data - and it is a dietary peptide in food, not an injectable peptide.
Named products: Not a drug; a therapeutic diet. Alpha-casozepine and L-tryptophan are the behaviourally active components. Do not extrapolate this result to alpha-casozepine or tryptophan supplements given separately - that was not what was tested.
Cohort study, 31 cats with acute non-obstructive idiopathic cystitis followed 5 weeks; 17 fed the test food and 14 other commercial diets. Recurrence (defined as at least one day with at least two of stranguria, periuria, haematuria, dysuria, pollakiuria) occurred in 5/17 on the therapeutic urinary stress diet versus 11/14 on other diets, a significant difference. Food FORMULATION (dry, moist or both) was NOT significant. MAJOR LIMITATION, state it plainly: OWNERS CHOSE WHICH FOOD TO FEED - this was not randomised, so owner motivation is confounded with diet, and the authors themselves write that a prospective clinical trial is needed to confirm the findings. Short follow-up (5 weeks). Species: CAT.
Perineal urethrostomy as salvage surgery for repeatedly obstructing male cats
Approved / guideline-backedFor a male cat that keeps re-obstructing despite correct medical and environmental management, surgically widening the urethral opening removes the mechanical bottleneck. It does not cure the underlying cystitis - the cat will still have episodes of straining and blood - but it converts a recurring life-threatening emergency into a manageable chronic problem. Owners must be counselled on a realistic complication profile before consenting.
Retrospective case series, 61 cats undergoing perineal urethrostomy: 11/61 (18%) developed minor short-term complications (within 2 months), 1/61 (1.6%) a major short-term complication requiring surgical revision, and 16/38 (42%) minor long-term complications, with NO major long-term complications identified; pre-operative urinary tract infection was significantly associated with minor short-term complications. A separate multicentre review of 247 cats found that patient positioning (sternal versus dorsal recumbency) did not affect surgical or anaesthetic duration or the likelihood of short- or long-term complications - i.e. surgeon preference is legitimate. Species: CAT.
When money is the barrier: a published low-cost alternative to euthanasia exists
Controlled trial in this speciesSome owners cannot fund catheterisation and hospitalisation, and the real-world alternative is often euthanasia. A published protocol combining sedation and analgesia, decompressive cystocentesis as needed, subcutaneous fluids and a quiet dark low-stress environment allowed most cats to urinate spontaneously without urethral catheterisation. This must be presented with its failure mode, not as a first choice.
Clinical trial in 15 male cats with urethral obstruction whose owners had DECLINED conventional treatment; cats with severe metabolic derangements or radiographic calculi were excluded. Protocol: acepromazine, buprenorphine and medetomidine, plus decompressive cystocentesis and subcutaneous fluids as needed. Treatment succeeded (spontaneous urination within 72 hours and discharge) in 11 of 15 cats. It FAILED in 4: uroabdomen in 3 and haemoabdomen in 1, and cats that failed had significantly higher serum creatinine than those that succeeded. Necropsy in 3 failures showed severe bladder inflammatory disease but no bladder rupture. The authors position this as a low-cost alternative to euthanasia when financial constraints prevent more extensive treatment. Species: CAT.
2025 iCatCare consensus guidelines on the diagnosis and management of lower urinary tract diseases in cats — International Cat Care (iCatCare) Veterinary Society, formerly the International Society of Feline Medicine (ISFM). This is the governing document for feline FLUTD, FIC, urolithiasis, urinary tract infection and urethral obstruction. The panel - chaired by Samantha Taylor and including Tony Buffington (the MEMO lineage), Danielle Gunn-Moore, Pieter Defauw and Certified Applied Animal Behaviorist Mikel M. Delgado - states that LUTS are similar despite different underlying causes, which creates a diagnostic challenge; that FIC, the most common cause, is challenging to manage due to a complex pathogenesis involving organs outside the lower urinary tract; that urethral obstruction is a life-threatening complication; and that recurrent LUTS can lead to relinquishment or euthanasia of affected cats. Complementary documents: the 2025 iCatCare guideline is supported for analgesia by the 2022 ISFM Consensus Guidelines on the Management of Acute Pain in Cats (Steagall PV, et al. J Feline Med Surg. 2022;24(1):4-30. PMID 34937455. DOI 10.1177/1098612X211066268) and, for any chronic NSAID use, by the 2024 ISFM and AAFP consensus guidelines on the long-term use of NSAIDs in cats (Taylor S, et al. J Feline Med Surg. 2024;26(4). PMID 38587872. DOI 10.1177/1098612X241241951); for the stone-forming subset, by the ACVIM Small Animal Consensus Recommendations on the Treatment and Prevention of Uroliths in Dogs and Cats (Lulich JP, et al. J Vet Intern Med. 2016;30(5):1564-1574. PMID 27611724. DOI 10.1111/jvim.14559). Note that the panel's own framing is that its information is based on available literature, expert opinion and panel experience - it is a consensus document, not a meta-analysis, and much of feline FIC management rests on expert opinion because the controlled trials that exist are largely negative.
How it is diagnosed
- Triage for obstruction BEFORE anything else: palpate for a large, firm, painful bladder and assess for bradycardia, hypothermia and weakness. This decision is made in the first minutes of the visit, because an obstructed cat needs decompression and potassium/electrolyte management, not an outpatient workup (Taylor 2025 iCatCare consensus, PMID 39935081).
- Complete urinalysis on a properly collected sample, including urine specific gravity and sediment examination. Sediment findings drive the next step - crystalluria, bacteriuria, red and white cell counts. In obstructed male cats, higher pyuria, haematuria and urine protein:creatinine ratio distinguished obstructed from non-obstructed FIC cats (Defauw 2011, PMID 22075439).
- Quantitative urine culture, interpreted by age. Bacterial UTI was 18.9% of fully investigated FLUTD cats overall, but 12.9% in cats under 10 years versus 41.8% in cats 10 and over (Dorsch 2014, PMID 25119631). A young cat with LUTS usually does NOT have an infection, and empirical antibiotics in that cat are a diagnostic and stewardship error.
- Imaging - survey radiography of the whole urinary tract and/or ultrasound - to look for uroliths, urethral plugs, bladder wall and mass lesions. Urolithiasis was 7.0% and urethral plugs 10.3% of FLUTD cases (Dorsch 2014, PMID 25119631), and neoplasia reached 13.4% in cats 10 years and over, so imaging is not optional in an older cat.
- Biochemistry, electrolytes and acid-base in any obstructed or systemically unwell cat, including potassium and ionised calcium. Ionised calcium was significantly higher in survivors than non-survivors of urethral obstruction, and hypocalcaemia was more prevalent in non-survivors (Segev 2010, PMID 21145768).
- Only after infection, stones, plugs, anatomic disease and neoplasia have been excluded is idiopathic cystitis the diagnosis. FIC is defined by exclusion, and the iCatCare panel is explicit that LUTS are similar despite different underlying causes, which creates a diagnostic challenge (Taylor 2025, PMID 39935081).
- Structured environmental and behavioural history as part of the medical workup, not as an afterthought: number and siting of litter boxes, litter type, cleaning frequency, water sources, diet form (dry versus canned), number of cats, conflict between them, indoor-only housing, and recent household changes such as a move. This history is what a multimodal environmental modification plan is built from (Buffington 2006, PMID 16616567), and the 2025 iCatCare panel treats FIC pathogenesis as involving organs outside the lower urinary tract (PMID 39935081).
- Recurrent or refractory cases: submit any retrieved stone or plug for quantitative mineral analysis (5 of 37 cats in a struvite dissolution trial had stones that failed to dissolve and proved to be 100% ammonium urate or 100% calcium oxalate - Lulich 2013, PMID 24094262), and consider advanced imaging or cystoscopy per the ACVIM urolith consensus (Lulich 2016, PMID 27611724).
Where a biologic fits
Our own product, graded by the same rule
Feline adipose stem-cell exosomes have been characterised in the laboratory and carry microRNAs with anti-inflammatory and regenerative functions, but no cat with idiopathic cystitis has yet received them in any published study - so this is a research direction, not a treatment, and PetSmartMeds makes no claim that any stem-cell, exosome or peptide product treats feline lower urinary tract disease.
What exists
CATS, EXOSOMES/EXTRACELLULAR VESICLES: exactly one publication, and it contains no treated cat. Rubini et al. isolated exosomes from feline adipose-derived stem cells (fADSCs) and sequenced their microRNA cargo by Illumina sequencing, reporting miRNAs with plausible proliferative, angiogenic, immunomodulatory and anti-inflammatory functions (named: fca-miR-221, fca-let-7f-5p, fca-miR-337-5p, fca-miR-542-5p, fca-miR-24-3p, fca-miR-205, fca-miR-23a; anti-inflammatory fca-miR-193a-5p and fca-miR-127-3p; immune-regulatory fca-let-7a-5p and fca-miR-chrC1_18846-5p; antifibrotic fca-miR-219-5p). The title uses the words 'Therapeutic Potential', and that is exactly what it is - potential. Design: laboratory characterisation and functional annotation of miRNA content. No cat received anything. No clinical endpoint. No control group. Author affiliations include commercial entities: Rubini A and Calogero G at Ultravet Diagnostics, and Rubini G at ZetaRL - disclose this. Rubini A, Zanotti F, Licastro D, Calogero G, Bettini G, Piccoli C, Rubini G, Lovatti L, Zavan B. Nanotheranostics. 2025;9(1):38-51. PMID 39744099. DOI 10.7150/ntno.99383. A PubMed search for exosome AND cats AND cystitis returns this one record and nothing else (run 2026-09-12). CATS, MESENCHYMAL STROMAL CELLS: zero. A PubMed search for feline idiopathic cystitis combined with mesenchymal stem cell therapy and bladder returned 0 records (run 2026-09-12). The authoritative review of feline MSC clinical trials lists gingivostomatitis, chronic enteropathy, asthma and kidney disease as the indications with feline clinical data - idiopathic cystitis is not among them (Quimby JM, Borjesson DL. J Feline Med Surg. 2018;20(3):208-216. PMID 29478398. DOI 10.1177/1098612X18758590). CATS, PEPTIDES: zero. There is no controlled efficacy evidence in cats for BPC-157, TB-500/thymosin beta-4, KPV, LL-37, GHK-Cu or any other injectable peptide for any lower urinary tract indication; a PubMed search for 'BPC 157' combined with cats returns 0 records. The ONLY peptide-containing product with any supporting feline clinical data in this condition is a dietary one - alpha-casozepine plus L-tryptophan in a therapeutic food, in a non-randomised 31-cat cohort study (PMID 31532910). HUMANS, LABELLED AS HUMAN AND NOT TRANSFERABLE: human interstitial cystitis/bladder pain syndrome is where the cell-therapy work actually is. A phase I study injected human embryonic-stem-cell-derived MSCs submucosally by cystoscopy into 3 women with Hunner lesions with no product-related adverse events over 12 months (Shin JH, et al. Stem Cells Transl Med. 2022;11(10):1010-1020. PMID 36069837. DOI 10.1093/stcltm/szac065), and a single-centre randomised, double-blind, placebo-controlled phase 1/2a trial of the same product (MR-MC-01) in 22 patients reported significant reductions in ICQ and PUF scores, with global response assessment moderate-to-marked in 41.67% of 12 treated patients versus 25% of 4 placebo patients (Kyung YS, et al. Stem Cells Transl Med. 2025;14(5). PMID 40387787. DOI 10.1093/stcltm/szaf018). Note what that evidence is: a human trial, of a human embryonic-stem-cell-derived CELL product, delivered by cystoscopic submucosal injection under general anaesthesia, in a 4-patient placebo arm. It is not feline data, it is not an exosome, and it is not a route or a product any veterinary clinic is offering. OTHER SPECIES, FOR CONTEXT ONLY: DogStem (EMA EMEA/V/C/005829) is an authorised veterinary medicinal product containing EQUINE umbilical-cord-derived MSCs administered to DOGS - a xenogeneic product - with 51% of treated dogs versus 5% of placebo dogs meeting a force-plate gait endpoint at 8 weeks. That is canine osteoarthritis, not feline cystitis, and it establishes nothing here.
What has not been shown
There is no published study - randomised or otherwise, controlled or uncontrolled, single-case or series - in which ANY cat with feline idiopathic cystitis or FLUTD received mesenchymal stromal cells, an exosome or extracellular-vesicle preparation, conditioned medium, or an injectable peptide. Not one treated cat. Therefore the following do not exist and must never be implied: a feline efficacy signal, a feline dose, a feline route, a feline dosing interval, a feline recurrence-reduction figure, a feline safety dataset for intravesical or systemic exosome administration, or a comparison against any of the interventions that DO have feline data (canned food, MEMO, analgesia, dissolution diets). Nor is there a validated surrogate endpoint: no validated owner-completed clinical metrology instrument for feline FIC was located, so even a future trial would have to define its own outcome. Two further claims are specifically prohibited. First, 'immune-privileged' or 'immune-invisible' cells: Punzón E, García-Castillo M, Rico MA, Padilla L, Pradera A found, in a randomised controlled trial of intra-articular administration in 24 police working dogs, that BOTH equine umbilical-cord and canine adipose MSCs GENERATED ANTIBODY TITRES in the dogs, while no adverse events were detected (Front Vet Sci. 2023;10:1098029. PMID 37266387. DOI 10.3389/fvets.2023.1098029), so while safety was acceptable, immunological invisibility is not a defensible claim in any species. Second, US regulatory status: no animal cell, exosome, conditioned-medium or extracellular-vesicle product is FDA-approved for any species or indication; in the United States these are unapproved new animal drugs. Finally, the negative feline MSC record in an adjacent organ should temper enthusiasm rather than be ignored - in feline chronic kidney disease, intravenous cryopreserved allogeneic adipose MSCs caused vomiting during infusion in 2/5 cats and increased respiratory rate and effort in 4/5 cats with no clinically relevant benefit (Quimby JM, et al. Stem Cell Res Ther. 2013;4(2):48. PMID 23632128. DOI 10.1186/scrt198).
Sources
- The only feline FIC exosome paper - in-vitro miRNA characterisation, no treated cat — Rubini A, Zanotti F, Licastro D, Calogero G, Bettini G, Piccoli C, Rubini G, Lovatti L, Zavan B. Therapeutic Potential of Feline Adipose-Derived Stem Cell Exosomes in the Treatment of Feline Idiopathic Cystitis: A Characterization and Functional Analysis of miRNA Content. Nanotheranostics. 2025;9(1):38-51. PMID 39744099. DOI 10.7150/ntno.99383 https://doi.org/10.7150/ntno.99383
- Feline MSC clinical trial indications - idiopathic cystitis is NOT among them — Quimby JM, Borjesson DL. Mesenchymal stem cell therapy in cats: Current knowledge and future potential. J Feline Med Surg. 2018;20(3):208-216. PMID 29478398. DOI 10.1177/1098612X18758590 https://doi.org/10.1177/1098612X18758590
- Feline IV cryopreserved MSC safety signal (kidney disease) - vomiting 2/5, respiratory signs 4/5, no benefit — Quimby JM, Webb TL, Habenicht LM, Dow SW. Safety and efficacy of intravenous infusion of allogeneic cryopreserved mesenchymal stem cells for treatment of chronic kidney disease in cats: results of three sequential pilot studies. Stem Cell Res Ther. 2013;4(2):48. PMID 23632128. DOI 10.1186/scrt198 https://doi.org/10.1186/scrt198
- MSCs are NOT immune-privileged - both equine and canine MSCs raised antibody titres in dogs — Punzón E, García-Castillo M, Rico MA, Padilla L, Pradera A. Local, systemic and immunologic safety comparison between xenogeneic equine umbilical cord mesenchymal stem cells, allogeneic canine adipose mesenchymal stem cells and placebo: a randomized controlled trial. Front Vet Sci. 2023;10:1098029. PMID 37266387. DOI 10.3389/fvets.2023.1098029 https://doi.org/10.3389/fvets.2023.1098029
- Human interstitial cystitis phase 1/2a MSC trial - human, embryonic-derived, cystoscopic; NOT feline evidence — Kyung YS, Hong KS, Chung HM, Shin JH, Choo MS, Kim EY, Shin JM, Kang AR, Seo JW, Park J, Park SP. A single-center, phase 1/2a trial of hESC-derived mesenchymal stem cells (MR-MC-01) for safety and efficacy in interstitial cystitis patients. Stem Cells Transl Med. 2025;14(5). PMID 40387787. DOI 10.1093/stcltm/szaf018 https://doi.org/10.1093/stcltm/szaf018
- Human interstitial cystitis phase I MSC safety study (n=3) - human only — Shin JH, Ryu CM, Yu HY, Park J, Kang AR, Shin JM, Hong KS, Kim EY, Chung HM, Shin DM, Choo MS. Safety of Human Embryonic Stem Cell-derived Mesenchymal Stem Cells for Treating Interstitial Cystitis: A Phase I Study. Stem Cells Transl Med. 2022;11(10):1010-1020. PMID 36069837. DOI 10.1093/stcltm/szac065 https://doi.org/10.1093/stcltm/szac065
- The one peptide-containing product with any feline clinical data here is a DIET, and the study was not randomised — Naarden B, Corbee RJ. The effect of a therapeutic urinary stress diet on the short-term recurrence of feline idiopathic cystitis. Vet Med Sci. 2019;6(1):32-38. PMID 31532910. DOI 10.1002/vms3.197 https://doi.org/10.1002/vms3.197
- Governing guideline - what the feline specialty panel actually recommends for FIC — Taylor S, Boysen S, Buffington T, Chalhoub S, Defauw P, Delgado MM, Gunn-Moore D, Korman R. 2025 iCatCare consensus guidelines on the diagnosis and management of lower urinary tract diseases in cats. J Feline Med Surg. 2025;27(2). PMID 39935081. DOI 10.1177/1098612X241309176 https://doi.org/10.1177/1098612X241309176
Tracking response
How you know whether it is working
There is NO validated owner-completed clinical metrology instrument for feline idiopathic cystitis - a PubMed search for a validated owner questionnaire or severity score for feline lower urinary tract signs returned 0 records (run 2026-09-12). State that plainly rather than inventing a scale. What the published feline trials actually used, and what PetSmartMeds should therefore use, is a THREE-PART record: (1) an owner-kept daily LUTS diary with visual analogue scales for each sign - this is the method used in the 6-month randomised glucosamine trial, which also captured number of recurrences and days per episode; (2) a binary recurrence definition, taken verbatim from the diet cohort study - an episode of recurrence is at least one day with at least two of stranguria, periuria, haematuria, dysuria and pollakiuria; and (3) URINE SPECIFIC GRAVITY as the one objective, cheap, repeatable measure that tracks the intervention with the best feline evidence (water intake). USG fell from a mean 1.050 at enrolment to 1.036 one month after owners increased canned food, so a USG that has not moved is direct evidence the diet change did not actually happen. Owners can also be asked to count litter-box visits and photograph the litter, which is more reliable than recalled impressions. Do NOT adopt the feline pain instruments used for osteoarthritis (FMPI/FMPI-sf) here - they were developed and validated for musculoskeletal pain, not cystitis, and the FMPI additionally requires written permission from NC State before reproduction.
Diary and visual-analogue-scale method plus the USG shift: Gunn-Moore DA, Shenoy CM. Oral glucosamine and the management of feline idiopathic cystitis. J Feline Med Surg. 2004;6(4):219-25. PMID 15265477. DOI 10.1016/j.jfms.2003.09.007 (40 cats, 6 months; USG 1.050 at start vs 1.036 at one month, P < 0.01). Recurrence definition: Naarden B, Corbee RJ. Vet Med Sci. 2019;6(1):32-38. PMID 31532910. DOI 10.1002/vms3.197 (at least one day with at least two clinical signs). Trial-grade in-hospital monitoring template - repeated physical examination, daily urinalysis, a 5-day owner questionnaire after discharge and a 3-month telephone follow-up: Dorsch R, Zellner F, Schulz B, Sauter-Louis C, Hartmann K. J Feline Med Surg. 2016;18(11):925-933. PMID 26672127. DOI 10.1177/1098612X15621603. Long-term follow-up structure (6-month and 2-year recurrence, 22% and 24%): Segev G, Livne H, Ranen E, Lavy E. J Feline Med Surg. 2010;13(2):101-8. PMID 21145768. DOI 10.1016/j.jfms.2010.10.006. CRITICAL CAVEAT to publish alongside any before-and-after improvement: in the glucosamine trial the majority of cats in BOTH the active and placebo arms improved significantly from baseline (P < 0.001), which the authors attribute to 90% of owners switching to more canned food. Uncontrolled improvement in this condition is the expected result and is not evidence that a product worked.
Suggested cadence: ACUTE, UNOBSTRUCTED: owner records signs daily for 10-14 days. The pivotal feline data show most cats still have signs one week after presentation, so do not judge treatment at 48 hours and do not stop analgesia at discharge. Recheck examination and urinalysis at 5-7 days. AFTER AN OBSTRUCTION: re-examine within 24-48 hours of catheter removal (10 of 16 re-obstructions in the prazosin trial occurred while the cat was still hospitalised), then at 7 days, then at 1 month. Owners get explicit written instructions to return immediately for any straining without urine. DIET AND ENVIRONMENT CHANGES: measure urine specific gravity at baseline and again 4 weeks after the switch to canned food - that is the interval at which the published USG drop was demonstrated. Re-take the environmental history at 4 weeks, because MEMO plans decay. LONG TERM: owner check-in at 3, 6, 12 and 24 months, scoring recurrence with the two-signs-in-one-day definition. Use 6-month and 2-year recurrence as the honest benchmark (22% and 24% after urethral obstruction), not a 4-week snapshot. OLDER CATS: any cat 10 years or over with recurrent LUTS is re-worked up rather than re-treated - UTI was 41.8% and neoplasia 13.4% of causes in that age band. ALWAYS: if a cat on chronic NSAID therapy, recheck renal panel, USG, urine protein:creatinine ratio and blood pressure per the 2024 ISFM/AAFP NSAID guideline schedule.
Questions you can answer at home
- In the last 24 hours, did your cat pass a normal-sized puddle of urine at least once? (If the answer is no, or you are not sure, call us today.)
- How many times did your cat go into the litter box, and how many of those times did urine actually come out?
- Was there any pink, red or rusty colour in the urine or on the litter?
- Did your cat strain, hunch, cry or lick at itself before or after urinating - and was that more, the same, or less than yesterday?
- Did your cat urinate anywhere outside the litter box, and if so, where?
- What has your cat eaten and drunk today - how much canned or wet food, and did you see it drink?
- Anything different at home in the last week - a new pet or person, a move, building work, a change of litter, boxes not scooped, or another cat blocking the way to the box?
Last reviewed: 2026-09-12 · Every claim on this page carries a citation you can check. If one does not hold up, tell us and we will correct it. science@azzamedical.com
Build a profile for your pet
Tell us what you are dealing with and the site will show you only what applies.